(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
04 September 2025 (04.09.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/181803 A1

(51) International Patent Classification:
A61K 38/17 (2006.01) *C07K 14/705* (2006.01)
A61K 31/7072 (2006.01) *A61P 35/00* (2006.01)
A61K 39/395 (2006.01) *C07K 16/28* (2006.01)
A61K 39/00 (2006.01) *A61K 9/00* (2006.01)
C07K 19/00 (2006.01)

(21) International Application Number:
PCT/IL2025/050192

(22) International Filing Date:
26 February 2025 (26.02.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/559,224 29 February 2024 (29.02.2024) US
63/652,203 28 May 2024 (28.05.2024) US

(71) Applicant: **KAHR MEDICAL LTD.** [IL/IL]; 28 Dam HaMacbim Street, PO Box 9, 7178594 ModiIn Makabim-ReUt (IL).

(72) Inventors: **PEREG, Yaron**; 4 Adulam Street, P.O. Box 379, 6081404 Shoham (IL). **CHAJUT, Ayelet**; 7 Haim Herzog Street, 4813953 Rosh HaAyin (IL). **FOLEY-COMER, Adam**; 13 HaLevona Street, 4335546 RaAnana (IL).

(74) Agent: **EHRLICH, Gal** et al.; G.E. Ehrlich (1995) Ltd., Sky Tower, 13th Floor, 35 HaMasger Street, 6721407 Tel Aviv (IL).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2025/181803 A1

(54) Title: COMBINED TREATMENT WITH A SIRPalpha-4-1BBL FUSION PROTEIN FOR CANCER

(57) Abstract: Combined treatment with a SIRPα-4-lBBL fusion protein for cancer is provided. Accordingly, there is provided a combination of a SIRPa-4-lBBL fusion protein and at least two agents selected from the group consisting of an agent which inhibits activity or expression of a receptor-ligand combination PD1-PD-L1, an agent which inhibits activity or expression of a receptor-ligand combination VEGFR-VEGF, and Trifluridine/Tipiracil, for use in treating cancer in a subject in need thereof. Also provided a combination of a SIRPa-4-lBBL fusion protein and agent which inhibits a receptor tyrosine kinase signaling pathway, for use in treating cancer in a subject in need thereof.